{
  "claim_id": "claim_005",
  "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
  "document": "Liu_et_al.__2024_",
  "verification_stats": {
    "total_extracted": 8,
    "verified": 4,
    "rejected": 4,
    "verification_rate": 0.5
  },
  "verified_evidence": [
    {
      "id": 2,
      "quote": "Enrolled and Randomized n=723 vaccine Allocation Flu zone IIV4 n=122 18-44 years: n=57 45-64 years: n=65 Completed day 0 (n=110) 1 month (n=110) and 6 months (n=101) visit Fluarix IIV4 n=120 18-44 years: n=55 45-64 years: n=65 Completed day 0 (n=120) 1 month (n=118) and 6 months (n=107) visit ... RIV4 in Year 1 n=152",
      "supports_claim": true,
      "explanation": "The quote appears on page 2 of the document: 'Enrolled and Randomized n=723 accine Allocation Flu zone IIV4 n=122 18-44 years: n=57 45-64 years: n=65 Completed day 0 (n=110) 1 month (n=110) and 6 months (n=101) visit Fluarix IIV4 n=120 18-44 years: n=55 45-64 years: n=65 Completed day 0 (n=120) 1 month (n=118) and 6 months (n=107) visit e-enrolled in Year 2 and new enroll ees randomized n=684 (139*) ccIIV4 in Year 1 n=214 RIV4 in Year 1 n=152'. This matches the factual content of the quote to verify, listing the randomized allocation of participants to Fluarix IIV4 (a quadrivalent standard-dose vaccine) and RIV4 (Flublok quadrivalent), with the same numbers and structure.. The quote directly supports the claim. It shows that in the pivotal trial, participants were randomized to receive Fluarix IIV4 (a quadrivalent standard-dose vaccine) and RIV4 (Flublok quadrivalent). The explicit mention of both vaccines and their allocation confirms that Flublok (quadrivalent) was evaluated against Fluarix (quadrivalent standard-dose vaccine) in the pivotal trial, as the claim asserts.",
      "presence_explanation": "The quote appears on page 2 of the document: 'Enrolled and Randomized n=723 accine Allocation Flu zone IIV4 n=122 18-44 years: n=57 45-64 years: n=65 Completed day 0 (n=110) 1 month (n=110) and 6 months (n=101) visit Fluarix IIV4 n=120 18-44 years: n=55 45-64 years: n=65 Completed day 0 (n=120) 1 month (n=118) and 6 months (n=107) visit e-enrolled in Year 2 and new enroll ees randomized n=684 (139*) ccIIV4 in Year 1 n=214 RIV4 in Year 1 n=152'. This matches the factual content of the quote to verify, listing the randomized allocation of participants to Fluarix IIV4 (a quadrivalent standard-dose vaccine) and RIV4 (Flublok quadrivalent), with the same numbers and structure.",
      "support_explanation": "The quote directly supports the claim. It shows that in the pivotal trial, participants were randomized to receive Fluarix IIV4 (a quadrivalent standard-dose vaccine) and RIV4 (Flublok quadrivalent). The explicit mention of both vaccines and their allocation confirms that Flublok (quadrivalent) was evaluated against Fluarix (quadrivalent standard-dose vaccine) in the pivotal trial, as the claim asserts.",
      "original_relevance": "This quote lists the randomized allocation of participants to Fluarix IIV4 (a quadrivalent standard-dose vaccine) and RIV4 (Flublok quadrivalent), directly supporting that Flublok was evaluated against Fluarix in the pivotal trial."
    },
    {
      "id": 4,
      "quote": "Fluarix IIV4: Day 0 (n = 24), 1 m (n = 24), 6 m (n = 23); ccIIV4: Day 0 (n = 56), 1 m (n = 54), 6 m (n = 51); RIV4: Day 0 (n = 40), 1 m (n = 40), 6 m (n = 38).",
      "supports_claim": true,
      "explanation": "The quote appears on Page 6 of the document, in the following form: 'Flu zone IIV4: Day0 (n = 24), 1 m (n = 24), 6 m (n = 21); Fluarix IIV4: Day 0 (n = 24), 1 m (n = 24), 6 m (n = 23); ccIIV4: Day 0 (n = 56), 1 m (n = 54), 6 m (n = 51); RIV4: Day 0 (n = 40), 1 m (n = 40), 6 m (n = 38).' The factual content, numbers, and technical details match the quote to verify, with only minor formatting differences (e.g., inclusion of Flu zone IIV4 as well).. The quote provides explicit evidence that Flublok (RIV4, recombinant quadrivalent influenza vaccine) and Fluarix (IIV4, quadrivalent standard-dose vaccine) were both evaluated in the same trial, as shown by the reporting of participant numbers for each group at multiple time points. This directly supports the claim that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
      "presence_explanation": "The quote appears on Page 6 of the document, in the following form: 'Flu zone IIV4: Day0 (n = 24), 1 m (n = 24), 6 m (n = 21); Fluarix IIV4: Day 0 (n = 24), 1 m (n = 24), 6 m (n = 23); ccIIV4: Day 0 (n = 56), 1 m (n = 54), 6 m (n = 51); RIV4: Day 0 (n = 40), 1 m (n = 40), 6 m (n = 38).' The factual content, numbers, and technical details match the quote to verify, with only minor formatting differences (e.g., inclusion of Flu zone IIV4 as well).",
      "support_explanation": "The quote provides explicit evidence that Flublok (RIV4, recombinant quadrivalent influenza vaccine) and Fluarix (IIV4, quadrivalent standard-dose vaccine) were both evaluated in the same trial, as shown by the reporting of participant numbers for each group at multiple time points. This directly supports the claim that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
      "original_relevance": "This quote provides explicit evidence that Flublok (RIV4) and Fluarix (IIV4) were both evaluated in the same trial, with participant numbers given for each group."
    },
    {
      "id": 5,
      "quote": "Fluarix IIV4 18\u221244 years: Day 0 (n = 55), 1 m (n = 55), 6 m (n = 48); ... RIV4 18\u221244 years: Day 0 (n = 99), 1 m (n = 98), 6 m (n = 85); RIV4 45\u221264 years: Day 0 (n = 98), 1 m (n = 98), 6 m (n = 92);",
      "supports_claim": true,
      "explanation": "The quote appears on page 4 of the document: 'Fluarix IIV4 18\u221244 years: Day 0 (n = 55), 1 m (n = 55), 6 m (n = 48); ... RIV4 18\u221244 years: Day 0 (n = 99), 1 m (n = 98), 6 m (n = 85); RIV4 45\u221264 years: Day 0 (n = 98), 1 m (n = 98), 6 m (n = 92);'. The numbers and groupings match the quote to verify, and the context is a table/figure legend describing the allocation of participants to Fluarix IIV4 (a standard-dose quadrivalent vaccine) and RIV4 (Flublok quadrivalent recombinant vaccine) arms.. The quote provides explicit evidence that both Flublok (RIV4, quadrivalent recombinant) and Fluarix (IIV4, quadrivalent standard-dose) were administered to participants in the pivotal trial, with participant numbers given for each group and timepoint. This directly supports the claim that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
      "presence_explanation": "The quote appears on page 4 of the document: 'Fluarix IIV4 18\u221244 years: Day 0 (n = 55), 1 m (n = 55), 6 m (n = 48); ... RIV4 18\u221244 years: Day 0 (n = 99), 1 m (n = 98), 6 m (n = 85); RIV4 45\u221264 years: Day 0 (n = 98), 1 m (n = 98), 6 m (n = 92);'. The numbers and groupings match the quote to verify, and the context is a table/figure legend describing the allocation of participants to Fluarix IIV4 (a standard-dose quadrivalent vaccine) and RIV4 (Flublok quadrivalent recombinant vaccine) arms.",
      "support_explanation": "The quote provides explicit evidence that both Flublok (RIV4, quadrivalent recombinant) and Fluarix (IIV4, quadrivalent standard-dose) were administered to participants in the pivotal trial, with participant numbers given for each group and timepoint. This directly supports the claim that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
      "original_relevance": "This quote shows that both Fluarix (quadrivalent standard-dose) and Flublok (quadrivalent recombinant) were administered to participants in the pivotal trial, supporting the claim."
    },
    {
      "id": "comp_2",
      "quote": "Enrolled and Randomized n=723 vaccine Allocation Flu zone IIV4 n=122 18-44 years: n=57 45-64 years: n=65 Completed day 0 (n=110) 1 month (n=110) and 6 months (n=101) visit Fluarix IIV4 n=120 18-44 years: n=55 45-64 years: n=65 Completed day 0 (n=120) 1 month (n=118) and 6 months (n=107) visit e-enrolled in Year 2 and new enroll ees randomized n=684 (139*) ccIIV4 in Year 1 n=214 RIV4 in Year 1 n=152",
      "supports_claim": true,
      "explanation": "The quote appears on page 2 of the document: 'Enrolled and Randomized n=723 accine Allocation Flu zone IIV4 n=122 18-44 years: n=57 45-64 years: n=65 Completed day 0 (n=110) 1 month (n=110) and 6 months (n=101) visit Fluarix IIV4 n=120 18-44 years: n=55 45-64 years: n=65 Completed day 0 (n=120) 1 month (n=118) and 6 months (n=107) visit e-enrolled in Year 2 and new enroll ees randomized n=684 (139*) ccIIV4 in Year 1 n=214 RIV4 in Year 1 n=152'. The numbers and vaccine names match the quote to verify, with only minor formatting differences (e.g., 'accine' instead of 'vaccine', 'e-enrolled' instead of 're-enrolled'). The factual content and structure are preserved.. The quote lists the allocation of participants to different vaccine groups, including Fluarix IIV4 (a quadrivalent standard-dose vaccine) and RIV4 (Flublok Quadrivalent), in a randomized trial. This directly supports the claim that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
      "presence_explanation": "The quote appears on page 2 of the document: 'Enrolled and Randomized n=723 accine Allocation Flu zone IIV4 n=122 18-44 years: n=57 45-64 years: n=65 Completed day 0 (n=110) 1 month (n=110) and 6 months (n=101) visit Fluarix IIV4 n=120 18-44 years: n=55 45-64 years: n=65 Completed day 0 (n=120) 1 month (n=118) and 6 months (n=107) visit e-enrolled in Year 2 and new enroll ees randomized n=684 (139*) ccIIV4 in Year 1 n=214 RIV4 in Year 1 n=152'. The numbers and vaccine names match the quote to verify, with only minor formatting differences (e.g., 'accine' instead of 'vaccine', 'e-enrolled' instead of 're-enrolled'). The factual content and structure are preserved.",
      "support_explanation": "The quote lists the allocation of participants to different vaccine groups, including Fluarix IIV4 (a quadrivalent standard-dose vaccine) and RIV4 (Flublok Quadrivalent), in a randomized trial. This directly supports the claim that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
      "original_relevance": "This quote lists the vaccine allocation for the randomized participants, showing that both Fluarix IIV4 (a quadrivalent standard-dose vaccine) and RIV4 (Flublok Quadrivalent) were used in the trial, directly supporting the claim."
    }
  ],
  "rejected_evidence": [
    {
      "id": 1,
      "quote": "In this randomized trial (Clinical trials gov: NCT03722589), sera pre- and post vaccination with quadrivalent inactivated egg based (IIV4), cell culture based (ccIIV4), and recombinant (RIV4) influenza",
      "reason": "does not support claim",
      "original_explanation": "This quote explicitly states that the trial evaluated quadrivalent recombinant influenza vaccine (RIV4, which is Flublok) alongside quadrivalent inactivated egg-based (IIV4) and cell culture-based (ccIIV4) vaccines, confirming that Flublok (quadrivalent) was evaluated in the pivotal trial."
    },
    {
      "id": 3,
      "quote": "sera pre- and post vaccination with quadrivalent inactivated egg based (IIV4), cell culture based (ccIIV4), and recombinant (RIV4) influenza",
      "reason": "does not support claim",
      "original_explanation": "This quote confirms that the study compared the recombinant quadrivalent vaccine (Flublok) with quadrivalent inactivated vaccines, which include Fluarix, thus directly supporting the claim."
    },
    {
      "id": "comp_1",
      "quote": "acell culture based influenza vaccine (Flucelvax Quadrivalent by Seqirus, Inc., ccIIV4) and a recombinant influenza vaccine (Flublok Quadrivalent by Sanofi Pasteur, RIV4). RIV4 contains 3 times the i d 45 HA/d / ...d",
      "reason": "does not support claim",
      "original_explanation": "This quote explicitly identifies Flublok Quadrivalent (RIV4) as the recombinant influenza vaccine evaluated in the trial, and distinguishes it from the cell culture-based vaccine, supporting the claim that Flublok was one of the vaccines tested in the pivotal trial."
    },
    {
      "id": "comp_5",
      "quote": "Day 0 1 m 6 mccIIV4 45\u221264 years: Day 0 (n = 148), 1 m (n = 147), 6 m (n = 142); RIV4 18\u221244 years: Day 0 (n = 99), 1 m (n = 98), 6 m (n = 85); RIV4 45\u221264 years: Day 0 (n = 98), 1 m (n = 98), 6 m (n = 92); Micro neutralization titers (MN) were measured for A (H3 N2) virus, while hem agglutination inhibition (HI) titers were measured for A (H1 N1) pdm09, B/Victoria (B/VIC), and B/Yamagata (B/YAM) viruses. One way ANOVA corrected for multiple comparisons (Tukey'stest) was used to compare the GMTs of each time point among the 4 vaccine groups. Statistically significant differences",
      "reason": "does not support claim",
      "original_explanation": "This quote shows that RIV4 (Flublok Quadrivalent) and Fluarix IIV4 were both included as vaccine groups in the trial, and their immunogenicity was compared using statistical analysis, directly supporting the claim."
    }
  ],
  "model_used": "gpt-4.1"
}